Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acalabrutinib + venetoclax + durvalumab
- Development stage
- Phase 2
- Lead developer
- Mayo Clinic
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
acalabrutinib + venetoclax + durvalumab is a combination therapy being investigated by the Mayo Clinic for the treatment of Richter transformation (Richter syndrome) arising from chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This regimen combines three distinct therapeutic mechanisms: durvalumab, a monoclonal antibody that acts as an immune checkpoint inhibitor by targeting PD-L1; acalabrutinib, a second-generation Bruton's tyrosine kinase (BTK) inhibitor that blocks B-cell receptor signaling; and venetoclax, a BCL-2 inhibitor that promotes apoptosis in malignant B-cells. The combination aims to overcome the aggressive nature and poor prognosis of Richter syndrome by simultaneously targeting survival pathways and enhancing the immune system's ability to detect and destroy cancer cells.
- Other names
- acalabrutinib + venetoclax + durvalumabDurvalumab combination therapyAcalabrutinib, Venetoclax and Durvalumab
02
Targets
BTK (Bruton tyrosine kinase)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on acalabrutinib + venetoclax + durvalumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acalabrutinib + venetoclax + durvalumab.